Genmab — November 2019

E_L

Q: I noticed early you brought another CD38 into development. That's quite a long way behind both isatuximab and Darzalex.

E_L

A: Indeed, we did put a next-generation CD38 into the clinic. The rationale behind these next, wave of CD38 antibodies is to ask the question of whether they can rescue patients who have failed a frontline CD38 standard of care antibody.

E_L

We've engineered into these molecules enhanced properties that enable them to recruit immune cells to attack the malignancy in a more amplified way. The first of those has recently gone in the clinic.

E_L

We have another one coming along behind that that uses yet another immune mechanism. What we know so far about mechanisms of resistance to the standard of care CD38 antibodies, is that the levels of CD38 on the myeloma cell are reduced.

E_L

But CD38 still remains on the myeloma cell, however at lower levels. So the target is still relevant. And we feel there's sufficient retained expression for most patients that we can still go at that target but with these enhanced antibodies. So there would really be an attempt to rescue patients who failed a frontline standard care agent.

Sukkeralf

Genmab then nedds to speed up HexaBody CD38 so that they are not that far behind Sanofi

bibob

I'am sure they work hard with that.

Helge_LarsenPI-redaktør

Ses vi? https://www.proinvestor.com/debat/78610

Bulder

They have the money for it, so it shouldn't be a problem to speed it up a bit. And thx again E L.

E_L

a small new trial using BMS-986253 / HuMax-IL8 for NSCLC https://clinicaltrials.gov/ct2/show/NCT04123379

Bella1

Børsen nede 11.06?

Bella1

Fondsbørsen, forstås...

Bulder

følg med i chat nyheder

Solsen

Hvis ikke de åbner når vi ikke ATH og festen i dag...

bikube

Børsen åbner igen kl. 13.

E_L

a saw from this message from a Belgian University hospital that one of the area's BMS-986253 is used is Dermatological tumors/ melanoma https://www.uzgent.be/nl/zorgaanbod/mdspecialismen/Geneesmiddelenonderzoek/Lopende-studies/Paginas/Indicatoren-dermatologische-tumoren.aspx (clinicaltrials only mentioned 'advanced cancers' https://www.clinicaltrials.gov/ct2/show/study/NCT03400332?term=BMS-986253&show_locs=Y#locn )

Plimsoller

Så er de vist oppe igen. Kursen hoppede lige.

Bulder

allerede nyt børsstop

Plimsoller

Har de fået deres system fra den samme leverandør som Skat?

Bulder

yes, ansaldobreda